A novel integrated molecular imaging approach enables precise localization and quantification of heart damage, as well as accurate identification of disease subtypes. The dual PET/MR and PET/CMR technique also provides direct evidence supporting surgery as a cardio-protective intervention in these patients, offering a comprehensive strategy for managing primary aldosteronism. This research was presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting.

Julie Price, PhD, FSNMMI, has been named the 2025 recipient of the prestigious Paul C. Aebersold Award. Price is an investigator at Massachusetts General Hospital in the Department of Radiology, a Professor of Radiology at Harvard Medical School, and Director of PET Pharmacokinetic Modeling at the Athinoula A. Martinos Center for Biomedical Imaging in Boston, Massachusetts. The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2025 Annual Meeting.

Wynn Volkert, PhD, a trailblazer in nuclear medicine, has been named the 2025 recipient of the Georg Charles de Hevesy Nuclear Pioneer Award in recognition of his outstanding contributions to the field. The award was announced by the Society of Nuclear Medicine and Molecular Imaging (SNMMI) during its 2025 Annual Meeting, held June 21-24 in New Orleans.

A newly developed cardiac PET imaging technique offers a simpler way to detect significant coronary artery disease—eliminating the need for complex scanning protocols. This innovative approach, which maintains high diagnostic accuracy, has the potential to make advanced heart imaging more accessible and feasible, particularly during exercise stress testing. The study was presented at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2025 Annual Meeting, where it received top recognition as the Abstract of the Year.

Post-therapy imaging and dosimetry significantly enhance patient management, empowering clinicians to make more informed, personalized decisions in radiopharmaceutical therapy. A series of case studies presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting highlights how this approach improves patient outcomes, guides clinical decision-making, and drives meaningful changes in clinical practice.

Two newly developed PET imaging agents have been proven effective in identifying the histamine H3 receptor (H3R) that is highly expressed in neurological and psychiatric conditions. The novel agents have a long half-life, addressing key limitations of existing tracers and offering the potential to enable broader clinical imaging of H3R. This research was presented at the 2025 Society of Nuclear Medicine and Molecular Imaging Annual Meeting.

For the first time, a new PET imaging technique has successfully visualized three radiotracers in a single scan, according to findings presented at the Society of Nuclear Medicine and Molecular Imaging 2025 Annual Meeting. This innovation in multiplexed PET offers the potential to deliver a more comprehensive molecular profile of disease, enabling greater precision in both diagnosis and therapeutic assessment.